Background: Retroperitoneal schwannomas are rare. The purpose of this study was to present our experience with the diagnosis and treatment of 67 such tumors. Methods: Retrospective analysis of 67 patients with retroperitoneal schwannoma admitted to Peking University International Hospital from 2015 to 2021. Results: 67 patients presented with retroperitoneal schwannomas, 37 cases had no obvious clinical symptoms. 62 cases were completely excised, 5 cases were subtotal resection, 7 cases were combined with organ resection. The intraoperative blood loss was 300ml (20-9000ml), the tumor maximum size was 9cm (2.5-26cm), post-complication occurred in 6 cases (9.0%). Compared with abdominal retroperitoneal tumors, pelvic retroperitoneal tumors had larger tumor volume, more bleeding, higher proportion of block resection, and longer postoperative hospitalization time (P<0.05). The residual mass progressed slowly in 5 patients with subtotal resection, and no obvious malignant transformation occurred. Conclusion:Complete resection of schwannoma can achieve a good long-term prognosis. Patients with residual tumor after surgery progress slowly and rarely become malignant. We recommend early resection after the discovery of a pelvic retroperitoneal schwannoma. Keywords: Schwannoma; Retroperitoneal neoplasms; Postoperative complications
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.